Bottom line
XLV vs VHT: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and VHT (Vanguard Health Care Index Fund) have nearly the same top holdings — their top 25 positions are about 94% the same by weight.
But VHT is far broader, holding 407 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 0.09% — a difference of $1.00 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +7.2% for VHT (reporting dates differ).
Updated Nov 19, 2026
XLV vs VHT side by side
| XLV | VHT | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Vanguard |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.09% |
| Annual cost per $10k | $8 | $9 |
| 10-yr cost on $10k (prospectus) | $103 | $115 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +2.7% |
| 5-yr return (annualized) | +8.1% | +7.2% |
| 10-yr return (annualized) | +9.8% | +8.8% |
| Best quarter | +14.5% | +16.5% |
| Worst quarter | −12.7% | −13.1% |
| Net assets (fund) | $40.6B | $19.0B |
| Number of holdings | 65 | 407 |
| Portfolio turnover | 2% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | VHT | Difference |
|---|---|---|---|
| 2024 | +2.5% | +2.7% | −0.1% |
| 2023 | +2.0% | +2.5% | −0.5% |
| 2022 | −2.1% | −5.5% | +3.5% |
| 2021 | +25.9% | +20.5% | +5.4% |
| 2020 | +13.3% | +18.2% | −4.9% |
| 2019 | +20.7% | +22.0% | −1.3% |
| 2018 | +6.3% | +5.6% | +0.7% |
| 2017 | +21.7% | +23.3% | −1.6% |
| 2016 | −2.8% | −3.3% | +0.5% |
Source: Fund prospectus bar charts
Holdings overlap
23 of XLV's top 25 holdings also appear in VHT's top 25.
| Holding | XLV | VHT |
|---|---|---|
| Eli Lilly & Co | 16.51% | 14.04% |
| Johnson & Johnson | 10.64% | 8.47% |
| AbbVie Inc | 7.74% | 6.09% |
| UnitedHealth Group Inc | 6.57% | 5.45% |
| Merck & Co Inc | 5.52% | 4.66% |
| Amgen Inc | 3.40% | 2.87% |
| Thermo Fisher Scientific Inc | 3.24% | 2.93% |
| Abbott Laboratories | 2.75% | 2.35% |
| Gilead Sciences Inc | 2.73% | 2.64% |
| Intuitive Surgical Inc | 2.45% | 2.38% |
| Pfizer Inc | 2.39% | 2.35% |
| CVS Health Corp | 2.30% | 1.83% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.80% |
| Danaher Corp | 2.09% | 1.84% |
| Bristol-Myers Squibb Co | 2.05% | 1.84% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
VHT top 10
- Eli Lilly & Co — 14.04%
- Johnson & Johnson — 8.47%
- AbbVie Inc — 6.09%
- UnitedHealth Group Inc — 5.45%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 2.93%
- Amgen Inc — 2.87%
- Gilead Sciences Inc — 2.64%
- Intuitive Surgical Inc — 2.38%
- Pfizer Inc — 2.35%
FAQ
What is the difference between XLV and VHT?
Which is cheaper, XLV or VHT?
Should I own both XLV and VHT?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.